Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02257528 · ClinicalTrials.gov registry record · Phase 2

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

A Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 2
Development phase
26
Enrollment target
20
Study locations

NCT02257528: Active Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma, sponsored by National Cancer Institute (NCI).

NCT02257528 is a Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 26 participants, below the 122-participant average among 13 other Cervical Adenocarcinoma trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02257528, a Phase 2 study of Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
26 participants
Enrollment target
20
Study locations

Study Summary

This phase II trial studies the side effects and how well nivolumab works in treating patients with cervical cancer that has grown, come back, or spread to other places in the body. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.

Primary Outcome

Proportion of participants with objective tumor response. Objective tumor response is defined as complete or partial tumor response assessed by RECIST 1.1.

Conditions Studied

Cervical Adenocarcinoma Cervical Adenosquamous Carcinoma Recurrent Cervical Carcinoma Stage IV Cervical Cancer AJCC v6 and v7 Stage IVA Cervical Cancer AJCC v6 and v7 Stage IVB Cervical Cancer AJCC v6 and v7

Interventions

  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Nivolumab

Study Locations (20)

Alaska

  • Anchorage Associates in Radiation Medicine - Anchorage
  • Anchorage Radiation Therapy Center - Anchorage
  • Alaska Breast Care and Surgery LLC - Anchorage
  • Alaska Oncology and Hematology LLC - Anchorage
  • Alaska Regional Hospital - Anchorage
  • Alaska Women's Cancer Care - Anchorage
  • Anchorage Oncology Centre - Anchorage
  • Katmai Oncology Group - Anchorage
  • Providence Alaska Medical Center - Anchorage

California

  • Sutter Auburn Faith Hospital - Auburn
  • Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
  • Kaiser Permanente-Baldwin Park - Baldwin Park
  • Alta Bates Summit Medical Center-Herrick Campus - Berkeley
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
  • Mills-Peninsula Medical Center - Burlingame
  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park - Cameron Park
  • Eden Hospital Medical Center - Castro Valley
  • Sutter Davis Hospital - Davis

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham

Arkansas

  • CHI Saint Vincent Cancer Center Hot Springs - Hot Springs

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2015-05-18
Est. Completion 2026-03-17
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the registry record for NCT02257528 still lists

NCT02257528 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 122-participant average among 13 other Cervical Adenocarcinoma trials with a reported enrollment target (79% lower).

The record links to 6 conditions, with Cervical Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02257528 names 20 study sites across 4 states, led by Alaska, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT02257528 about?

NCT02257528 is a clinical study titled "Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer". This phase II trial studies the side effects and how well nivolumab works in treating patients with cervical cancer that has grown, come back, or spread to other places in the body. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.

What is the current status of trial NCT02257528?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2015-05-18. Estimated completion is 2026-03-17.

What conditions does trial NCT02257528 study?

This clinical trial studies the following conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma, Stage IV Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7.

What interventions are being tested in trial NCT02257528?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Nivolumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02257528?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02257528 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cervical Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02257528's enrollment target sits among peer trials

26 13th of 13 higher than 1 of 13 other Cervical Adenocarcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cervical Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02257528, the US trial registry maintained by the National Library of Medicine. NCT02257528 (small enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.